Lantheus (NASDAQ:LNTH) Releases FY 2025 Earnings Guidance

Lantheus (NASDAQ:LNTH) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 7.000-7.200 for the period, compared to the consensus estimate of 6.980. The company issued revenue guidance of $1.5 billion-$1.6 billion, compared to the consensus revenue estimate of $1.6 billion.

Wall Street Analyst Weigh In

Several research firms have commented on LNTH. JMP Securities reaffirmed a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. Truist Financial reaffirmed a “buy” rating and set a $120.00 price objective (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. The Goldman Sachs Group began coverage on Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective for the company. Finally, StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $131.86.

Lantheus Trading Up 16.5 %

Shares of LNTH stock opened at $93.25 on Thursday. The company has a market cap of $6.48 billion, a price-to-earnings ratio of 15.52 and a beta of 0.44. The stock has a 50 day simple moving average of $89.81 and a 200-day simple moving average of $96.78. Lantheus has a 12-month low of $56.44 and a 12-month high of $126.89.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. On average, equities analysts forecast that Lantheus will post 6.01 earnings per share for the current fiscal year.

Insider Activity at Lantheus

In related news, Director James H. Thrall sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the transaction, the director now directly owns 33,207 shares of the company’s stock, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.50% of the stock is currently owned by company insiders.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.